Variant "SGCG:p.Cys283*"
Search result: 1 record
Variant information
Gene:
Variant:
SGCG:p.Cys283* 
Mouse homolog:
Sgcg:p.Cys283Tyr 
dbSNP ID:
no data 
GWAS trait:
no data 
Modifier statisitcs
Record:
Disorder:
Reference:
Effect type:
Expressivity(1)  
Modifier effect:
Risk factor(1)  
Detail:
  • Target disease:
    Muscular Dystrophy (DOID_9884)
    Effect type:
    Expressivity 
    Modifier effect:
    Risk factor 
    Evidence:
    Study on mouse strains 
    Effect:
    Mutation in the γ-sarcoglycan is thought to contribute to the formation of intramolecular disulfide bridges, The loss of a disulfide bridge likely affects the trafficking of γ-sarcoglycan to the plasma membrane
    Reference:
    Title:
    Genetic modifiers of muscular dystrophy: implications for therapy.
    Species studied:
    Mouse
    Abstract:
    The genetic understanding of the muscular dystrophies has advanced considerably in the last two decades. Over 25 different individual genes are now known to produce muscular dystrophy, and many different private mutations have been described for each individual muscular dystrophy gene. For the more common forms of muscular dystrophy, phenotypic variability can be explained by precise mutations. However, for many genetic mutations, the presence of the identical mutation is associated with marked phenotypic range that affects muscle function as well as cardiac function. The explanation for phenotype variability in the muscular dystrophies is only now being explored. The availability of genetically engineered animal models has allowed the generation of single mutations on the background of highly inbred strain. Phenotypic variation that is altered by genetic background argues for the presence of genetic modifier loci that can ameliorate or enhance aspects of the dystrophic phenotype. A number of individual genes have been implicated as modifiers of muscular dystrophy by studies in genetically engineered mouse models of muscular dystrophy. The value of these genes and products is that the pathways identified through these experiments may be exploited for therapy.